G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
20 May 2021 - 7:01AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage
oncology company, today announced upcoming data presentations at
the American Society of Clinical Oncology (ASCO) annual meeting,
being held virtually June 4th through 8th. The presentations will
describe results from the Company’s study of its oral selective
estrogen receptor degrader (SERD), rintodestrant, in combination
with palbociclib for the treatment of ER+/HER2- advanced breast
cancer as well as data describing the effects of COSELA™
(trilaciclib) on T-cell activation and clonal expansion in patients
with newly diagnosed extensive-stage small cell lung cancer. A copy
of the posters will be made available on the G1 corporate website
on June 4, 2021.
Details for the posters and abstract are as
follows:
Title: Rintodestrant (G1T48),
an oral selective estrogen receptor degrader, in combination with
palbociclib for ER+/HER2- advanced breast cancer: Phase 1 results.
Session: Breast Cancer –
MetastaticDate: Available starting on June
04, 2021, 09:00 AM ETPoster
number: 1063
Title: Effects of trilaciclib
prior to chemotherapy ± atezolizumab on T-cell activation in
patients with newly diagnosed extensive-stage small cell lung
cancer.Session: Lung Cancer – Non-Small Cell
Local-Regional/Small Cell/Other Thoracic
CancersDate: Available starting on: May 19,
2021, 05:00 PM ETeAbstract: e20582
Title: PRESERVE 2: A phase 3,
randomized, double-blind trial of trilaciclib versus placebo in
patients receiving first- or second-line gemcitabine and
carboplatin for locally advanced unresectable or metastatic
triple-negative breast cancer.
Session: Breast Cancer –
MetastaticDate: Available starting on June
04, 2021, 09:00 AM ETPoster
number: TPS1107
About G1 TherapeuticsG1
Therapeutics, Inc. is a commercial-stage biopharmaceutical company
focused on the development and commercialization of next generation
therapies that improve the lives of those affected by cancer,
including the Company’s first commercial product, COSELA™
(trilaciclib). G1 has a deep clinical pipeline and is executing a
tumor-agnostic development plan evaluating COSELA in a variety of
solid tumors, including colorectal, breast, lung, and bladder
cancers. G1 Therapeutics is based in Research Triangle Park, N.C.
For additional information, please
visit www.g1therapeutics.com and follow us on
Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo and
COSELA™ and the COSELA logo are trademarks of G1 Therapeutics,
Inc.
G1 Therapeutics Contact:Will
RobertsVice President, Investor Relations & Corporate
Communications919-907-1944wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Jul 2024 to Aug 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Aug 2023 to Aug 2024